Andrew Östör, Lila Glotfelty, Cuiyong Yue, Jonathon Rocco, and Joseph F. Merola

This poster describes a post hoc analysis of the ongoing Phase 3 KEEPsAKE 1 and 2 trials evaluating the long-term maintenance of clinical response to risankizumab (RZB) through ~4 years. Enrolled patients were adults with active psoriatic arthritis (PsA) with inadequate response or intolerance to ≥1 csDMARD (KEEPsAKE 1 and 2) and/or 1–2 biologic therapies (KEEPsAKE 2). Patients included in this analysis received subcutaneous continuous RZB 150 mg, including open-label RZB after Week 28. Treatment response was evaluated by ACR20/50/70, MDA, PASI90 responses, and meaningful pain reduction (≥10mm visual analog scale [VAS]). In patients who achieved an RZB treatment response at Weeks 24 or 52, most patients maintained response through Week 196. Thus, RZB achieved long‑term efficacy in patients with active PsA.

OLE LIMITATION: In an open-label extension, there is a potential for enrichment of the long-term data in the remaining patient populations since patients who are unable to tolerate or do not respond to the drug often drop out.

AO DISCLOSURE: Patients with missing data at a specific time are not included, which may enrich the population and increase the response rates.

The Medical Affairs + Health Impact department of AbbVie Inc. is the copyright owner of this presentation and has paid RheumNow to host this content. AbbVie is solely responsible for all written content within this presentation.

© 2025 AbbVie Inc. All rights reserved. RISN-US-00060-MC v1.0 Approved March 2025